NCT05177146 (DEEPP) is a NA clinical trial of Intravenous Ketamine (IV) in Bipolar Disorder (BD), sponsored by Centre for Addiction and Mental Health.

Who is sponsoring NCT05177146?

NCT05177146 is sponsored by Centre for Addiction and Mental Health.

What drugs are being tested in NCT05177146?

Interventions in NCT05177146: Intravenous Ketamine (IV).

What condition does NCT05177146 study?

NCT05177146 studies Bipolar Disorder (BD), Suicidality.

Is NCT05177146 still recruiting?

NCT05177146 is currently completed. Last updated 6 February 2025.

Last reviewed 2025-02-06 · How we verify

NCT05177146: DEEPP

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Neural Correlates of Ketamine's Anti-suicidal Effects in Bipolar Depression

Completed NA Last updated 6 February 2025

What this trial tests

NA trial testing Intravenous Ketamine (IV) in Bipolar Disorder (BD) in 16 participants. Completed in 10 January 2025.

Timeline

4 May 2022

Primary endpoint
10 January 2025

10 January 2025

Quick facts

Lead sponsor	Centre for Addiction and Mental Health
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	16
Start date	4 May 2022
Primary completion	10 January 2025
Estimated completion	10 January 2025
Sites	1 location across Canada

Drugs / interventions tested

Intravenous Ketamine (IV) — full drug profile →

Conditions studied

Bipolar Disorder (BD) — all drugs for Bipolar Disorder (BD) →
Suicidality — all drugs for Suicidality →

Sponsor

Centre for Addiction and Mental Health — full company profile →

Who can join

Adults 24 to 65, any sex, with Bipolar Disorder (BD) or Suicidality. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Bipolar disorder is characterized by manic episodes and episodes of extreme depressive feelings, also known as bipolar depression (BD). Although clinical data does not suggest significant differences in the severity of depressive symptoms between bipolar and unipolar depression, patients with BD are found to be more likely to experience suicidal ideation and suicide attempts. Innovative treatments for suicidality in patients with BD are needed to address tolerability and slow effect limitations of current interventions. Using an open label pilot study, this trial aims to examine the effect of Intravenous (IV) ketamine treatment on acute suicidality in patients with BD. Moreover, the study aims to explore the neurophysiological mechanisms of ketamine's action directly from the cortex in patients with BD, in order to understand the biological mechanism underlying ketamine's therapeutic action.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Ketamine for bipolar depression: an updated systematic review.
Fancy F, Haikazian S, Johnson DE, Chen-Li DCJ, et al · · 2023 · cited 15× · PMID 37771417 · DOI 10.1177/20451253231202723
Neural Correlates of the DEEPP (Anti-suicidal Response to Ketamine in Treatment-Resistant Bipolar Depression) Study: Protocol for a Pilot, Open-Label Clinical Trial.
Knyahnytska Y, Zomorrodi R, Kaster T, Voineskos D, et al · · 2023 · PMID 36573651 · DOI 10.2196/41013

Verify or expand the search:

Other recruiting trials for Bipolar Disorder (BD)

Currently open trials in the same condition.

NCT07213492 — Multimodal Intervention to Support Hospital-to-Community Transition in Bipolar Disorder · NA · recruiting
NCT07589647 — Research on the Efficacy and Safety of Targeted Suprachiasmatic Nucleus Electrical Stimulation for Improving Metabolic D · NA · recruiting
NCT07306039 — Feasibility of eLi12 · NA · active not recruiting
NCT07404085 — Epigenetic Enhancement of Cognitive Training in Aging Mood Disorder Populations · NA · recruiting
NCT07306468 — Effects of Schizophrenia and Bipolar Disorder on Exercise Capacity, Pulmonary Function, and Quality of Life · recruiting

Other Centre for Addiction and Mental Health trials

Trials by the same sponsor.

NCT07211438 — Evaluating the Role of Psilocybin Monitors in Psilocybin Therapy for Treatment Resistant Depression · Phase 2 · not yet recruiting
NCT07146633 — Efficacy of an EMDR App for PTSD and SUD · NA · recruiting
NCT07228923 — Development and Evaluation of a Theory and Evidence-based Intervention to Reduce Hazardous Alcohol Consumption Among Tre · NA · not yet recruiting
NCT07105449 — THC Titration of High-Potency Cannabis Concentrates · NA · not yet recruiting
NCT06928935 — Digital Dialectical Behavioural Therapy (d-DBT) for Youth at Clinical High Risk (CHR) for Psychosis · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05177146 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Centre for Addiction and Mental Health
Last refreshed: 6 February 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05177146.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing